enGene beats Q1 estimates, cash runway extends to 2028
Biotechnology company posts $0.44 loss per share, exceeds analyst expectations as BLA filing for detalimogene remains on track
enGene Holdings reported a smaller-than-expected loss in its first quarter, bolstering investor confidence in the clinical-stage biotechnology company as it advances toward a critical regulatory filing for its bladder cancer treatment.
The Montreal-based company posted a net loss of $0.44 per share for the quarter ended January 31, surpassing analyst expectations of a $0.55 loss. Net loss attributable to common shareholders totaled approximately $29.8 million, compared with $24.6 million, or $0.48 per share, in the same period last year.
Operating expenses rose to $31.2 million from $26.6 million in the prior year, driven by increased personnel and clinical costs related to the LEGEND trial and preparations for a Biologics License Application submission, alongside scaling of general and administrative functions.
Most notably, enGene reported cash, cash equivalents, and marketable securities of $312.5 million as of January 31—a position the company expects will fund operations through the second half of 2028. This substantial runway provides significant flexibility as enGene advances its lead program, detalimogene voraplasmid, toward regulatory submission.
The company remains on track to submit a BLA for detalimogene in the second half of 2026, targeting patients with high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS). The treatment has shown compelling efficacy in the Phase 2 LEGEND trial, with data demonstrating a 63% complete response rate at any time point. For patients treated under an amended protocol, the complete response rate reached 62% at six months among 37 evaluable patients.
The trial has also demonstrated a favorable tolerability profile, with treatment-related adverse events occurring in 42% of patients, most of which were mild or moderate. Dose interruptions were rare at 1.6%, and discontinuations occurred in only 0.8% of patients, according to recent clinical updates.
All five patients who completed the nine-month assessment maintained complete response, and the amended protocol now includes maintenance dosing, allowing patients in complete response at 12 months to continue receiving detalimogene on a dose-reduced schedule for up to three years. This approach aims to evaluate potential improvements in response durability while reducing patient burden.
Analysts remain bullish on enGene's prospects. The company holds a consensus target price of $23.91, representing significant upside from its current trading level around $8.68. Of 11 analysts covering the stock, 10 rate it a buy or strong buy, with just one hold rating and no sell recommendations. Institutional ownership stands at 97.9%, reflecting strong professional investor confidence.
The 52-week range for enGene shares spans from $2.65 to $12.25, with the stock currently trading near the midpoint of that range. The company's market capitalization stands at approximately $581 million.
enGene expanded its clinical footprint during the quarter by adding trial sites in Europe and Asia for the LEGEND study. All four cohorts of the trial are now open for enrollment, including the pivotal cohort and three additional cohorts covering various NMIBC patient populations.
Looking ahead, the company anticipates announcing enrollment completion of the LEGEND pivotal cohort and providing additional updates on other study cohorts in the second half of 2026. The BLA submission remains on schedule for the second half of next year, with potential FDA approval anticipated in 2027.
The substantial cash position extending into 2028 provides enGene with considerable operational flexibility, insulating the company from immediate financing pressures as it approaches critical regulatory milestones. This financial strength, combined with promising clinical data, positions the company to execute on its development strategy without the need for near-term capital raises that could dilute existing shareholders.